Published:
January 13, 2022
Services:
CPG More...
Priorities:
“Better-for-You” Transformation More...
Topics:
Aging Technologies | AI in Healthcare More...
Activities:
Policy
Further Reading
Singaporean biotech firm Lucence continues to advance its liquid biopsy technology for early cancer diagnostics
News Commentary | March 26, 2021
In partnership with Waseda University, Lucence plans to develop a high‑speed liquid biopsy platform for early cancer detection. The technology will use laser‑based imaging to capture high‑resolution images of circulating tumor cells from blood samples. Lucence developed a single liquid biopsy test ... Not part of subscription
China approves OrgiMed's NGS-based genomic alteration tumor test
News Commentary | September 08, 2021
The test, which was made in collaboration with Bayer, was developed to detect rare NTRK gene fusions in both children and adults. It is a companion diagnostic to a gene inhibitor therapy that specifically targets NTRK cancers. Clients should note how genomic sequencing can be utilized for diagnostic... Not part of subscription
NHS launches world's largest liquid biopsy trial, which could potentially detect 50 types of cancer
News Commentary | September 17, 2021
NHS will use GRAIL's Galleri test in this study, which aims to recruit 140,000 volunteers in eight areas of England. Besides being touted as the world's first and largest clinical trial of its kind, the more important significance of this study is that it is being spearheaded by one of the largest ... Not part of subscription
by Brian O'Shea
The U.S. FDA has given 23andMe approval to expand its genetic health risk report by screening for a G84E mutation in the HOXB13 gene. This mutation has been linked to an increase in prostate cancer. A recent study showed that males with a G84E gene mutation were 66% more likely to have prostate cancer than their noncarrier peers. 23andMe's test was shown to be 99% effective in finding this biomarker. 23andMe adds this test to two other FDA-approved cancer screenings, one for breast cancer and one for colorectal cancer. It remains the only company with direct-to-consumer screening products. Clients in both the biomarkers and genomics spaces should take note of 23andMe's success in this field and look for partnership opportunities.
For the original news article, click here .